Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well ...

L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 ...

Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call Transcript October 28, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.11, ...

Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment?

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
TipRanks on MSN

Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference

Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody ...
Healthcare in Europe

Pathologists at the heart of precision oncology

Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, ...

Cardiff Oncology: Preparing For A Defining 2026

Cardiff Oncology (CRDF) is a speculative buy with potential blockbuster gains ahead of its 2026 data readout. Read here for ...